Vialwirebiotech, curated
September 30, 2026, 7:39 PM
September 18, 2026
- 12:35 PM · TechCrunch12:35 PMManus seeks $4B valuation in new $500M fundraise as it resumes independent ops — TechCrunch
- 12:00 PM · BioWorld12:00 PMSino Biopharm nears approvals with HER2 ADC, IL-4R antibody filings — BioWorld
- 12:00 PM · BioWorld12:00 PMXenon: FOS read-across in MDD, BD hitches with Kv7? — BioWorld
- 12:00 PM · BioWorld12:00 PMElectra’s $350M IPO supports late-stage ipsoprubart mAb in sHLH — BioWorld
- 9:47 AM · Pharmaceutical Technology9:47 AMFDA approves first gene therapy for Sanfilippo syndrome type A — Pharmaceutical Technology
- 9:00 AM · BioWorld9:00 AMGoa Therapeutics unveils GOA-26 for acute alcohol poisoning — BioWorld
- 9:00 AM · BioWorld9:00 AMNew spinout Ariadne Bio focused on apathy in Parkinson’s disease — BioWorld
- 5:39 AM · Pharmaceutical Technology5:39 AMOna Therapeutics to develop ADC with WuXi’s payload-linker platform — Pharmaceutical Technology
- 5:30 AM · Drug Discovery World5:30 AMArrowhead’s RNA therapy silences two genes simultaneously — Drug Discovery World
- 5:00 AM · SCMP — Tech
- 4:00 AM · Drug Discovery World4:00 AMCompany achieves key milestone in drug discovery for rare bone cancer — Drug Discovery World
- 4:00 AM · SCMP — Tech
September 17, 2026
- 11:00 PM · SCMP — Tech11:00 PMByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom — SCMP — Tech
- 5:39 PM · BioPharma Dive5:39 PMLisata deal propels Marea’s drug pipeline to Wall Street — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMSettlement resolves SEC charges against Ubiome founders — BioWorld
- 12:00 PM · BioWorld12:00 PMMed-tech M&A value nears $80B, best pace since 2022 — BioWorld
- 12:00 PM · BioWorld12:00 PMRealheart artificial heart shows sixfold reduction in hemolysis — BioWorld
- 12:00 PM · BioWorld12:00 PMLongeveron to carry on? Shortfall in HLSH phase IIb — BioWorld
- 12:00 PM · BioWorld12:00 PMSK Biopharm takes 1st Bio’s LRRK2/c-Abl inhibitor in $315M deal — BioWorld
- 12:00 PM · BioWorld12:00 PMNo 510(k) exemption for CAD, CADt devices — BioWorld
- 12:00 PM · BioWorld12:00 PMOrbis, Novo in $1.4B cardiometabolic deal for macrocycles — BioWorld
- 11:55 AM · BioPharma Dive11:55 AMNovo partners with Orbis, deepening investment in oral peptide drugs — BioPharma Dive
- 11:09 AM · BioPharma Dive11:09 AMNorth Immunology joins biotech reverse merger boom with Aethlon deal — BioPharma Dive
- 9:27 AM · Pharmaceutical Executive9:27 AM<![CDATA[FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMNIH grant supports Inomagen’s gene therapy for atrial fibrillation — BioWorld
- 9:00 AM · BioWorld9:00 AMAkeso’s AK-158D1 cleared for clinic in China for solid tumors — BioWorld
- 9:00 AM · BioWorld9:00 AMRoche describes path to phase II MAGL inhibitor for multiple sclerosis — BioWorld
- 9:00 AM · BioWorld9:00 AMSeries E financing at Circle Pharma to advance cyclin D1 program — BioWorld
- 9:00 AM · BioWorld9:00 AMVaxthera to license Codagenix’s Syn17D-YF yellow fever vaccine — BioWorld
- 9:00 AM · BioWorld9:00 AMRubedo’s RLS-1496 to enter clinic in new indication — BioWorld
- 9:00 AM · BioWorld9:00 AMRegcell adds $66M to take Nobel-winning Tregs to clinic — BioWorld
- 7:55 AM · Drug Discovery World7:55 AMAmivantamab shown to extend survival in advanced NSCLC — Drug Discovery World
- 6:30 AM · STAT News6:30 AMSTAT+: A Sellas immunotherapy study, long delayed, will end in failure — STAT News
- 6:10 AM · Drug Discovery World6:10 AMCommunity study tests respiratory protective nasal spray — Drug Discovery World
- 6:00 AM · BioPharma Dive6:00 AMRoche, Dualitas team up to find bispecific drugs for immune diseases — BioPharma Dive
- 5:26 AM · Pharmaceutical Technology5:26 AMCellares and GenomeFrontier to assess automated GF-CART01 production — Pharmaceutical Technology
- 4:58 AM · Bloomberg — Technology4:58 AMDeepMind Offshoot Emulate Closes In on $700 Million Seed Round — Bloomberg — Technology
- 4:40 AM · Pharmaceutical Technology4:40 AMViatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy — Pharmaceutical Technology
- 3:42 AM · STAT News